MitoxantroneCytarabineIdarubicinDaunorubicinAntineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteRemission InductionEtoposideConsolidation ChemotherapyLeukemia, MyeloidAntineoplastic AgentsAntimetabolites, AntineoplasticDrug Administration ScheduleAnthraquinonesVidarabineArabinonucleosidesDoxorubicinTreatment OutcomeDrug Resistance, NeoplasmThioguanineVincristinePrednisoneAmsacrineCyclophosphamideATP-Binding Cassette TransportersMethotrexateLymphoma, Non-HodgkinDrug Resistance, MultiplePrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseLeukemia, Myeloid, Accelerated PhaseSurvival AnalysisDisease-Free SurvivalSalvage TherapySurvival RateInduction ChemotherapyDrug EvaluationTopotecanP-GlycoproteinRecurrenceMeningeal CarcinomatosisNeoplasm ProteinsTransplantation, AutologousInjections, SpinalLeukemic InfiltrationTeniposideMelphalanInfusions, IntravenousDose-Response Relationship, DrugBlast CrisisCombined Modality TherapyDrug Screening Assays, AntitumorCytidine MonophosphateRazoxaneTopoisomerase InhibitorsLeukemiaCladribineCyclosporinsCarmustineLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAsparaginaseDrug AgonismPrednisoloneIntercalating AgentsDeoxycytidine KinaseLeukemia, Myelomonocytic, Acute6-MercaptopurineTaxoidsDexamethasoneMyelodysplastic SyndromesArabinonucleotidesEstramustineGranulocyte Colony-Stimulating FactorLeukemia, Promyelocytic, AcuteCardiotoxinsAntibiotics, AntineoplasticCentral Nervous System NeoplasmsAntibodies, Monoclonal, Murine-DerivedHematopoietic Stem Cell TransplantationPrognosisArabinofuranosylcytosine TriphosphateHL-60 CellsProstatic NeoplasmsNeutropeniaDNA Topoisomerases, Type IIAnemia, Refractory, with Excess of BlastsCell Survival